Synthetic Human Secretin in Children With Autism

NCT00036244 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL

Last updated 2005-08-05

No results posted yet for this study

Summary

The purpose of the study is to determine whether multiple doses of secretin are safe and effective in the treatment of children with autism.

Conditions

Interventions

DRUG

RG1068 (Synthetic Human Secretin)

Sponsors & Collaborators

  • Repligen Corporation

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
SINGLE_GROUP

Eligibility

Min Age
32 Months
Max Age
59 Months
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2002-04-30
Completion
2004-01-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00036244 on ClinicalTrials.gov